Navigation Links
Sarasota's Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimer's Disease Research
Date:12/14/2007

Third-Party Japanese Study Suggests Drug Improves Memory

SARASOTA, Fla., Dec. 14 /PRNewswire/ -- The Roskamp Institute today announced that its promising new drug application for the treatment of Alzheimer's disease has received positive validation from an independent human clinical study conducted at the Tokyo Medical University in Japan. The study, which suggests the drug, Nilvadipine, can prevent the onset of Alzheimer's disease in patients with memory problems, is detailed in the International Journal of Geriatric Psychiatry, a highly prestigious medical research journal.

The Japanese study was conducted over the course of a 20-month period, where a group of 15 amnestic mild cognitive impairment (MCI) patients with essential hypertension were divided into two groups. A group of eight participants were randomly allocated to take the drug, Nilvadipine, while the other seven remaining participants were designated to take the drug, Amlodipine.

The study found that the group treated with Nilvadipine had stabilized their decline in memory over the 20 months; whereas, the group treated with Amlodipine had continued to suffer loss of cognitive function, which was double that of the small decline in the Nilvadipine controlled group.

"Although the study was conducted with a small sample size, this third- party validation is extremely encouraging, as there appears to be a strong protective effect from developing Alzheimer's in memory-troubled patients who were given Nilvadipine," said Dr. Michael Mullan, director of the Roskamp Institute, who has been researching the drug for its use in Alzheimer's disease.

The Roskamp Institute, which owns the worldwide proprietary rights to use Nilvadipine for Alzheimer's disease, has been conducting its own human clinical study in partnership with the Trinity College Institute of Neuroscience in Dublin, Ireland, and has recently reported in March that the use of the drug in Alzheimer's patients is receiving positive safety reviews.

While the drug, Amlodipine, is one of the top drugs sold in the United States for the treatment of hypertension (high blood pressure), Nilvadipine, is currently not available in the U.S. However, the Roskamp Institute plans to introduce Nilvadipine to the U.S. Food and Drug Administration as a part of its phase II study early next year.

"As the authors of the Japan study propose, our Institute's researchers are planning to investigate whether the Japan study finding can be replicated in a larger participant study," said Dr. Fiona Crawford, associate director of the Roskamp Institute, who has been working alongside Dr. Mullan in researching Nilvadipine for its use in Alzheimer's disease. "As we continue to move forward in our studies, we are hopeful that we are well on our way to finding a drug that will be useful in slowing down or preventing this devastating disease."

In addition, the Roskamp Institute is looking for volunteers who have been diagnosed with Alzheimer's disease or Multiple Sclerosis to participate in Roskamp's ongoing research studies. If you or someone you know is interested in participating, please contact our Clinical Trials Division at (941) 256- 8018.

The Roskamp Institute is a not-for-profit research Institute located in Sarasota and Tampa, Florida, that is dedicated to understanding the causes of, and finding cures for, neuropsychiatric and neurodegenerative disorders and addictions with an emphasis on Alzheimer's disease. The Institute's Memory Clinics also offer comprehensive cognitive and medical assessment toward differential diagnosis of Alzheimer's disease and offers treatments and disease management options once the diagnostic evaluation is complete.

For more information, please contact the Roskamp Institute in Sarasota at (941) 752-2949, the Roskamp Institute Clinical Trials Division in Sarasota at (941) 256-8018 the Roskamp Institute Memory Center in Tampa at (813) 979-2008, or visit us online at http://www.RoskampInstitute.com.


'/>"/>
SOURCE The Roskamp Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. Sports Legacy Institute Announces Findings of Forensic Examinations on Wrestler Chris Benoits Brain
3. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
6. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
7. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
8. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
9. American Meat Institute Calls WCRF Panel Recommendations on Meat Consumption Extreme and Unfounded
10. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
11. American Legion Anticipates Institute of Medicine Report on Gulf War Veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... bioLytical Laboratories (das "Unternehmen"), ein Weltführer bei schnellen ... HIV-Selbsttests  in einer Version mit geringeren Kosten einzuführen.  ... ... New: INSTI Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444833 ) ...
(Date:11/30/2016)... Research and Markets has announced the addition of the ... report to their offering. ... The cerebrospinal fluid (CSF) acts as ... is circulated though the brain and its ventricles, the spine and the ... the brain changes significantly. As a result, intracranial ...
(Date:11/30/2016)...  Millennium Dental Technologies, Inc. announced that it has again ... of the State of California , County ... California,s Uniform Trade Secrets act, Unfair ... practices which are untrue and misleading, as well as other ... the second time in three years that Millennium found it ...
Breaking Medicine Technology:
(Date:11/30/2016)... ... November 30, 2016 , ... The Fertility Centers of ... a Cigna Infertility Center of Excellence. The Cigna Center of Excellence recognizes participating ... honor to be designated a Cigna Infertility Center of Excellence," said Fertility Centers ...
(Date:11/30/2016)... ... 2016 , ... "I hate when the mixture of saliva and toothpaste runs ... inventor from Bridgewater, N.J. "I thought that there had to be a way to ... the patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush handle ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For Discovery, ... the opening of a new eating disorder treatment center location in Palm Beach ... adults and adolescents, both males and females ages 10 and older with eating ...
(Date:11/30/2016)... MA (PRWEB) , ... November 30, 2016 , ... ... for treating injured workers have been a focus of public policymakers and system ... Compensation Research Institute (WCRI) released its Medical Price Index for Workers’ Compensation, ...
(Date:11/30/2016)... ... November 30, 2016 , ... The Clinical Data Interchange Standards ... Binding Guidance goes into effect next month. Sponsors whose studies start after December ... Standards Catalog. The current FDA Data Standards Catalog specifies the use of CDISC ...
Breaking Medicine News(10 mins):